184 related articles for article (PubMed ID: 15624748)
1. The medical uses and side effects of etanercept with a focus on cutaneous disease.
Scheinfeld N
J Drugs Dermatol; 2004; 3(6):653-9. PubMed ID: 15624748
[TBL] [Abstract][Full Text] [Related]
2. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
3. Etanercept for the treatment of psoriasis and psoriatic arthritis.
Gottlieb AB
Dermatol Ther; 2004; 17(5):401-8. PubMed ID: 15379775
[TBL] [Abstract][Full Text] [Related]
4. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
Paul C; Solignac M
Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
[No Abstract] [Full Text] [Related]
5. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
6. Etanercept (Enbrel) -- an update.
Goffe B
Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
[TBL] [Abstract][Full Text] [Related]
7. Henoch-Schönlein purpura after etanercept therapy for psoriasis.
Lee A; Kasama R; Evangelisto A; Elfenbein B; Falasca G
J Clin Rheumatol; 2006 Oct; 12(5):249-51. PubMed ID: 17023811
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept].
Mrowietz U; Barth J; Boehncke WH; Rosenbach T; Wozel G
J Dtsch Dermatol Ges; 2005 Jun; 3(6):470-2. PubMed ID: 15892851
[No Abstract] [Full Text] [Related]
9. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
Zhou H
J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
12. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
13. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.
Zeltser R; Valle L; Tanck C; Holyst MM; Ritchlin C; Gaspari AA
Arch Dermatol; 2001 Jul; 137(7):893-9. PubMed ID: 11453808
[TBL] [Abstract][Full Text] [Related]
14. Etanercept therapy in children with juvenile rheumatoid arthritis.
Hung JJ; Huang JL
J Microbiol Immunol Infect; 2005 Dec; 38(6):444-6. PubMed ID: 16341346
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
16. Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report.
Liang TC; Yang YH; Lin YT; Chiang BL
J Microbiol Immunol Infect; 2005 Dec; 38(6):447-50. PubMed ID: 16341347
[TBL] [Abstract][Full Text] [Related]
17. Etanercept: efficacy and safety for approved indications.
Kerensky TA; Gottlieb AB; Yaniv S; Au SC
Expert Opin Drug Saf; 2012 Jan; 11(1):121-39. PubMed ID: 22074366
[TBL] [Abstract][Full Text] [Related]
18. Etanercept and demyelinating disease in a patient with psoriasis.
Sukal SA; Nadiminti L; Granstein RD
J Am Acad Dermatol; 2006 Jan; 54(1):160-4. PubMed ID: 16384777
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
20. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
